FTC cracks down on ‘negative option’ marketing

By Shane Starling

- Last updated on GMT

Related tags Federal trade commission Ftc

The Federal Trade Commission (FTC) has settled with two weight loss dietary supplement companies it found to be exploiting consumers by offering them free trials that led to unwanted product commitments.

The practice is known as ‘negative option’ marketing – debiting consumer bank accounts when they fail to cancel an offer after the free period has expired.

In one case – JAB Ventures along with Jason Brailow were fined $7,803,425, but ordered to pay only $610,000 due to a lack of cash. Complete Weightloss Center, the marketers of a product called Woman’s UltraSlim, was hit with a $2,532,014 judgment, but ordered to pay only $3,000 now.

The FTC noted that full judgment would be imposed if the defendants are found to have misrepresented their financial condition.

Wrongdoing

All of the defendants were charged with violations of the FTC Act:

· Making false or unsubstantiated weight-loss and related claims

· Failing to disclose adequately that consumers who order a “free” sample are enrolled in a continuity program, that their accounts will be debited or charged to pay for the program, that they must cancel to avoid extra shipments and debits and charges, and how and when they must cancel to avoid the debits or charges

· Debiting or charging accounts of consumers who cancelled or tried to cancel, or those who were not adequately informed of the negative option features or terms and conditions, and therefore did not provide express informed consent for the debits or charges.

Some of the brands owned by the two companies include LeanLife PM, Burn Fat 2, Hoodia 66, Hoodia Thin, HoodiaGordonii, and RxZyte.

The typical scheme involved customers being billed about $100 every few months for unwanted products after their free trial ended. They were forced to give credit card details to gain the free trial and pay for shipping and handling.

For this the defendents were charged with violating the Electronic Fund Transfer Act and Regulation E for improperly debiting consumers’ accounts.

The FTC noted that companies are required by law to, “clearly and conspicuously disclose, before asking for money or billing information, all costs, all conditions regarding a product or service, and all terms and conditions of any offer with a negative option feature.”

FDA actions

The FTC works with the FDA and other bodies to police how dietary supplements are sold and marketed.

The crack-down comes at the same time as increased FDA activity in the weight loss area – it recently produced a list of transgressors that stretched to almost 70 products and included banned ingredients such as sibutramine, rimonabant, phenolphthalein and bumetanide.

“A large percentage of these products either contain dangerous undeclared ingredients or they might be outright fraudulent on the ingredients and have no effect at all,”​ said Michael Levy, the director of the FDA’s division of New Drugs and Labeling Compliance. “We don’t think consumers should be using these products.”

Related topics Regulation Weight management

Related news

Show more

Related products

show more

MOROSIL:INGREDIENT OF THE YEAR

MOROSIL:INGREDIENT OF THE YEAR

Content provided by BIONAP BIOACTIVE NATURAL PRODUCTS | 07-Mar-2024 | Product Brochure

MOROSIL™ has won as Ingredient of the Year in the category Weight Management at 2023 Nutraingredient USA. MOROSIL ™ is a standardized extract derived from...

In Weight Management Go Beyond with Slendacor®

In Weight Management Go Beyond with Slendacor®

Content provided by PLT Health Solutions | 22-Feb-2024 | White Paper

Slendacor® is a synergistic, patented formulation of three standardized herbal extracts: turmeric (Curcuma longa), moringa (Moringa oleifera) and curry...

Polyphenol extracts as weight management catalysts

Polyphenol extracts as weight management catalysts

Content provided by DolCas Biotech, LLC. | 18-Jan-2024 | White Paper

Viable natural product options for "healthy weight management" in the age of Ozempic and other GLP-1 inhibitors will require targeted innovations...

Related suppliers

Follow us

Products

View more

Webinars